KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Operating Leases (2019 - 2025)

Novartis Ag's Operating Leases history spans 5 years, with the latest figure at $1.6 billion for Q4 2024.

  • For Q4 2024, Operating Leases rose 973.97% year-over-year to $1.6 billion; the TTM value through Dec 2024 reached $1.6 billion, up 973.97%, while the annual FY2024 figure was $1.6 billion, 973.97% up from the prior year.
  • Operating Leases for Q4 2024 was $1.6 billion at Novartis Ag, up from $146.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.0 billion in Q4 2020 and bottomed at $146.0 million in Q4 2023.
  • The 5-year median for Operating Leases is $1.6 billion (2024), against an average of $1.4 billion.
  • The largest annual shift saw Operating Leases crashed 90.51% in 2023 before it soared 973.97% in 2024.
  • A 5-year view of Operating Leases shows it stood at $2.0 billion in 2020, then decreased by 19.15% to $1.6 billion in 2021, then dropped by 5.12% to $1.5 billion in 2022, then plummeted by 90.51% to $146.0 million in 2023, then skyrocketed by 973.97% to $1.6 billion in 2024.
  • Per Business Quant, the three most recent readings for NVS's Operating Leases are $1.6 billion (Q4 2024), $146.0 million (Q4 2023), and $1.5 billion (Q4 2022).